Because of the potential for interaction with CYP2D6 inhibitor(paroxetine and fluoxetine, quinidine) dosages of atomoxetine needs to be adjusted to prevent side effects from a higher concentration of atomoxetine. STRATTERA should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon or early evening. Atomoxetine HCl is also available in the strength of 10, 18, 25, 40, 60, 80, and 100 mg hard capsules. Atomoxetine has a United States (US) boxed warning for suicidal ideation in children and adolescents.
The use of atomoxetine for attention-deficit hyperactivity disorder (ADHD). Medicines are a part of a comprehensive treatment program that includes behavioral therapy. The diagnosis of ADHD must have been confirmed by a specialist. Strattera was the first and only non-stimulant medication approved for ADHD treatment in the United States by the Food and Drug Administration (FDA).
Stimulants should not be used with patients who have co-existing conditions such as untreated glaucoma, structural heart defects, and uncontrolled seizures. Strattera is often used in such circumstances. Children and adolescents who start on atomoxetine require close monitoring for suicidal ideation and unusual changes in behavior. It is used as part of a comprehensive treatment program that includes behavioral therapy.